News

WKTV NewsChannel 24d
Grateful for Graham 5K Run, Walk Raises Funds for Rare Genetic Disorder
Hundreds of people gathered in New Hartford Saturday morning for the fourth Annual Grateful for Graham 5K Run and Walk.
Q&A: Two decades of research lead to treatment for rare, painful skin condition
Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...
Managed Healthcare Executive5d
Common Intestinal Worm Drug Shows Promise Against Rare Skin Cancer
In mice with human Merkel cell carcinoma, pyrvinium pamoate significantly reduced tumor growth, potentially offering a new ...
Investigational gene therapy gives children with rare immune disorder a new lease on life
An investigational gene therapy has successfully restored immune function in all nine children treated with the rare and life ...
Contract Pharma7d
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease
The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.
Pharmaceutical Technology on MSN7d
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
EurekAlert!8d
Gene therapy restores immune function and extends lives of children with rare immune disorder
Two years after receiving an investigational gene therapy as part of a clinical trial co-led by UCLA’s Dr. Donald Kohn, nine children born with a life-threatening immune disorder are living free of ...
BioWorld8d
Abeona’s rare skin disease gene therapy approved by FDA
Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.
Watauga Democrat8d
FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic ...
Medscape8d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
Asianet Newsable on MSN8d
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease
ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, ...
Fierce Pharma8d
Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease
Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).